Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination

Valeria Orrù(Institute of Genetic and Biomedical Research), Francesco Cucca(University of Sassari), Magdalena Żołędziewska(Institute of Genetic and Biomedical Research), Francesca Virdis(Institute of Genetic and Biomedical Research), Maristella Steri(Institute of Genetic and Biomedical Research), Annalisa Loizedda(Institute of Genetic and Biomedical Research), Monia Lobina(Institute of Genetic and Biomedical Research), M. Marini(Institute of Genetic and Biomedical Research), M. Paola Castelli, Jessica Frau(University of Cagliari), Paolo Castiglia(University of Sassari), Maria Grazia Piras(Institute of Genetic and Biomedical Research), Paola Chessa(University of Sassari), Roberto Ignazio Zarbo(University of Sassari), Michele Marongiu(Institute of Genetic and Biomedical Research), Paolo Solla(University of Sassari), Lorena Lorefice(University of Cagliari), Matteo Floris(University of Sassari), Valeria Lodde(University of Sassari), Daniele Carmagnini(University of Cagliari), Maristella Pitzalis(Institute of Genetic and Biomedical Research), Maura Mingoia(Institute of Genetic and Biomedical Research), Marzia Fronza(University of Cagliari), Sandra Lai(Ospedale Microcitemico), Giuseppe Delogu(Sapienza University of Rome), Elisa Carta(University of Cagliari), Maria Laura Idda(University of Cambridge), Marcella Devoto(Children's Hospital of Philadelphia), Valentina Serra(Institute of Genetic and Biomedical Research), Silvy Pilotto(University of Ferrara), Gabriele Farina(University of Verona), Eleonora Cocco(University of Cagliari), Rafaela Mostallino(University of Cagliari), Edoardo Fiorillo(Institute of Genetic and Biomedical Research), Marco Masala(Ospedale Microcitemico)
Frontiers in Immunology
July 15, 2024
Cited by 4


Related Papers